Shares of U.S. biotech giant Moderna (NASDAQ: MRNA) closed trading on Friday, June 26, with a strong 12% surge. This spike marked the culmination of an impressive six-month rally: since the start of the year, the stock's value has soared by 125.51%. The market is clearly overestimating the company's prospects, and there are several fundamental reasons for this.

The key catalyst was the unanimous vote of the FDA's Vaccines and Related Biological Products Advisory Committee on June 18. All 9 experts supported a positive risk-benefit assessment for the experimental seasonal influenza vaccine mFLUSIVA (mRNA-1010) for people over 50. Such unanimity in biotech is extremely rare and significant. It virtually eliminated regulatory uncertainty ahead of the final decision expected on August 5. If approved, mFLUSIVA would become the first seasonal flu vaccine in the U.S. created on an mRNA platform.

Wall Street remains cautious despite the euphoria

Despite the explosive growth, Wall Street analysts are not yet rushing to join the widespread optimism. Piper Sandler raised its price target for MRNA to $77, and Jefferies to $53, maintaining a "hold" rating. However, the median forecast for the stock is just $43.45 — significantly below current quotes. The market has recorded 16 "hold" recommendations, and insider transactions are predominantly sales (75 recent operations). Experts do not expect significant revenue from the flu vaccine before 2027.

Not just vaccines: new structure and ambitious plans

In parallel, Moderna reorganized its business, carving out three key areas: vaccines, oncology, and rare diseases. This news alone lifted quotes by about 6.3%. However, the real buzz was generated by the company's plans to invest in production capacities in Germany, including sites that BioNTech intends to close. Market participants perceived this move as a long-term bet on scaling up ahead of the launch of new products in 2027–2028. At Science Day on June 25, management also presented an expanded development portfolio, including programs for in vivo CAR-T and T-cell engineering for oncology and autoimmune diseases.

My analysis: Moderna's 125% growth over six months is a classic case of "buying on expectations." The market is already pricing in the success of the flu vaccine and future breakthroughs in oncology. However, the current valuation ($120+ per share) looks overly optimistic, given that real cash flows from new products will not begin until at least 2027. Investors should be prepared for high volatility: any negative news from the FDA or delays in clinical trials could trigger a sharp correction. For now, this is a bet on the future, not on fundamentals.